Perform Another (Advanced) Search

1.  Study Posting (333) Trial #163103, Ovarian Cancer, Bismarck, ND
...Study Posting (333) Trial #163103, Ovarian Cancer, Bismarck, ND Trial Information Advanced Ovarian Cancer To investigate the efficacy and safety of BIBF 1120 plus chemotherapy as compared to ...
View Page

2.  Study Posting (5261) Trial #147022, Ovarian Cancer, West Palm Beach, FL
...platinum-resistant ovarian cancer The study will enroll adult patients with inoperable metastatic or locally advanced ovarian cancer resistant to platinum-based therapy (i.e., progression during platinum-based therapy or progression ...
View Page

3.  Newly Approved Drug Therapies (65) Ethyol (amifostine), Alza,
...approved to reduce the renal toxicity associated with repeated administration of chemotherapy in subjects with advanced ovarian cancer. Currently, there are only limited data on the effects of Ethyol on the efficacy ...
View Page

4.  Study Posting (2348) Trial #85477, Peritoneal Cancer, New York, NY
...your initial standard chemotherapy. The purpose of this study is to examine whether women with advanced ovarian cancer who have no evidence of disease after the completion of initial chemotherapy live longer ...
View Page

5.  CenterWatch: List of Newly Approved Drug Thearapies
...1995 Ethyol (amifostine) ; Alza; Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer, Approved December 8, 1995 Fosamax (alendronate sodium) ; Merck; Treatment for osteoporosis in women after ...
View Page

6.  CenterWatch Clinical Research Profile (5490) Trial #2256, Legacy Pharma Research, Bismarck, ND
...Trials The following trial(s) are actively recruiting patients: • Advanced Non-Small Cell Lung Cancer • Advanced Ovarian Cancer • Advanced Stage Non-small Cell Lung Cancer • Chemotherapy Induced Anemia in Patients with Metastatic ...
View Page

7.  CenterWatch: New Medical Therapies in Disease Category (203), Non-Hodgkin's Lymphoma
...a phase III trial investigating Orathecin (rubitecan) , a topoisomerase I-inhibitor for the treatment of advanced ovarian cancer. Results showed that 7% (13/196) of subjects given Orathecin experienced either a complete ...
View Page

8.  CenterWatch: New Medical Therapies in Disease Category (390), Metastatic Cancer
...a phase III trial investigating Orathecin (rubitecan) , a topoisomerase I-inhibitor for the treatment of advanced ovarian cancer. Results showed that 7% (13/196) of subjects given Orathecin experienced either a complete ...
View Page

9.  CenterWatch: New Medical Therapies in Disease Category (36), Prostate Cancer
...a phase III trial investigating Orathecin (rubitecan) , a topoisomerase I-inhibitor for the treatment of advanced ovarian cancer. Results showed that 7% (13/196) of subjects given Orathecin experienced either a complete ...
View Page

10.  CenterWatch: New Medical Therapies in Disease Category (186), Ovarian Cancer
...a phase III trial investigating Orathecin (rubitecan) , a topoisomerase I-inhibitor for the treatment of advanced ovarian cancer. Results showed that 7% (13/196) of subjects given Orathecin experienced either a complete ...
View Page

11.  CenterWatch: Oncology Approved Drug Therapies
...1995 Ethyol (amifostine) ; Alza; Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer, Approved December 8, 1995 Intron A (Interferon alfa-2b, recombinant) ; Schering-Plough; An adjuvant ...
View Page

12.  CenterWatch: Obstetrics/Gynecology Approved Drug Therapies
...1995 Ethyol (amifostine) ; Alza; Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer, Approved December 8, 1995 Femstat 3 (butoconazole nitrate 2%) ; Procter & Gamble, Roche; Over the ...
View Page

13.  CenterWatch: Endocrinology Approved Drug Therapies
...1995 Ethyol (amifostine) ; Alza; Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer, Approved December 8, 1995 Fosamax (alendronate sodium) ; Merck; Treatment for osteoporosis in women after ...
View Page

14.  CenterWatch: Clinical Trials in Category (186) Ovarian Cancer
...of shingles and shingles-related complications in immunocompromised individuals North Dakota Bismarck : Legacy Pharma Research Advanced Ovarian Cancer Oklahoma Tulsa : Cancer Care Associates Research Study of Carboplatin and DOXIL plus Bevacizumab in ...
View Page